See if you qualify for this lawsuit
Quick form — a real person will review your info and reach out if you may have a case.
Tepezza is an IV infusion drug approved by the FDA in 2020 for thyroid eye disease — a condition linked to Graves' disease that causes the eyes to bulge, redden, and cause double vision. It was celebrated as a breakthrough treatment.
But as more patients were treated, reports began emerging of a troubling side effect: hearing loss. Some patients developed ringing in the ears (tinnitus). Others experienced permanent hearing loss that didn't go away after treatment ended.
Case reports published in The Journal of Clinical Endocrinology & Metabolism in 2021 described patients experiencing significant hearing changes after Tepezza.1 The FDA updated Tepezza's label in 2023 to add a hearing risk warning — but for many patients, that warning came too late.2 If you received Tepezza infusions and developed hearing problems, take two minutes to check if you qualify.
What the Tepezza Lawsuit Is About
Tepezza is made by Horizon Therapeutics, which was acquired by Amgen in 2023. Lawsuits allege that Horizon failed to adequately study and disclose the risk of hearing damage before putting Tepezza on the market.
Research published in 2021 in the Journal of Clinical Endocrinology & Metabolism found that a significant percentage of patients treated with Tepezza reported hearing symptoms during or after treatment, including high-frequency hearing loss and tinnitus.1 Some patients' hearing did not recover even after stopping the drug.
The FDA's 2023 label update acknowledged the risk — but the lawsuits argue the company had access to information suggesting this risk years earlier and failed to act.2 An active MDL is currently receiving cases in the Northern District of Illinois.3
Who May Qualify
You may qualify if both of the following apply:
- You received Tepezza (teprotumumab-trbw) infusions — typically for thyroid eye disease.
- After treatment, you developed hearing loss, ringing in the ears (tinnitus), or any change in hearing that did not exist before treatment.
Two minutes — fill out the free form below to check.
Tell us about your Tepezza treatment and any hearing changes you noticed. A real person will review your info and reach out if you may have a case.
Start Free Case Check →What Could This Mean for You?
If you qualify, you may be owed money for the hearing loss you suffered, medical costs, and the impact on your quality of life. Hearing loss can be permanent and life-altering — affecting your ability to work, communicate, and enjoy daily life.
We will not quote you a specific number. What any case may be worth depends entirely on your individual situation — how many infusions you received, how severe your hearing loss is, your medical history, and how your case resolves. Anyone who gives you a specific dollar figure at this stage is guessing — and we won't do that.
What we can say: checking is free, takes two minutes, and you pay nothing out of pocket unless your case wins.
Filing Deadline
Deadlines to file vary by state. The MDL in Illinois is actively receiving cases — but you still need to act before your own state's filing window closes.3 Don't delay. The sooner you check, the more options you will have. Once the deadline in your state passes, you cannot file — even if you clearly would have qualified.
How the Process Works
Step 1 — Fill out the free form
No cost, no commitment. Takes about two minutes. A real person on our intake team reviews every submission.
Step 2 — A lawyer reviews your Tepezza treatment history and symptoms
They look at how many infusions you received and what hearing changes you experienced. If it looks like you may qualify, someone reaches out. If you don't hear back within a week, please contact another firm before your state's deadline passes.
Step 3 — You pay nothing unless you receive money
Attorneys work on contingency — no out-of-pocket fees. If your case doesn't recover money, you owe nothing. Ever.
Step 4 — Your case is filed in the MDL or appropriate court
Your case joins the active MDL in Illinois or is filed in the appropriate court. Most people never have to appear in a courtroom.
Common Questions
Sources
- 1 Kahaly, G.J. et al. "Teprotumumab for Thyroid-Associated Ophthalmopathy." The Journal of Clinical Endocrinology & Metabolism, 2021.
- 2 FDA Drug Safety Communication: Tepezza (teprotumumab-trbw) – Hearing Loss and Tinnitus. U.S. Food & Drug Administration, 2023.
- 3 PACER: MDL filings, In Re: Tepezza Marketing, Sales Practices, and Products Liability Litigation. U.S. District Court, Northern District of Illinois.